nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

15.04.2020 | short review

My personal highlights of ESMO 2019 regarding urogenital cancer

verfasst von: Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Summary

The field of uro-oncology has become more and more important in the past 3 years. ESMO 2019 once again had more highlights in this growing field of medical oncology. The 2019 ESMO annual meeting was an outstanding conference, especially in uro-oncology. Trials with potential for changing the standard of care and novel therapy approaches were presented in bladder cancer and renal cell carcinoma.

Vorheriger Artikel ESMO 2019—personal highlights in gastrointestinal cancer

Nächster Artikel The role of pathology in sarcoma

Grande E, Galsky M, Arranz Arija JA, et al. IMvigor130: efficacy and safety from a phase 3 study of Atezolizumab as Monotherapy or combined with platinum-based chemotherapy vs placebo + PBC in previously untreated locally advanced or metastatic Urothelial carcinoma. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.047.CrossRef

Hoimes CJ, et al. EV-103: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma—initial results. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.CrossRef

Tagawa, et al. TROPHY-U-01: initial results of a phase 2 open-label study of sacituzumab givotecan in patients with metastatic urothelial cancer after failure of platinum-based regimens or immunotherapy. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.049.CrossRef

Van der Heijden MS, et al. Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.003.CrossRefPubMed

Grimm MO, et al. A tailored Immunotherapy approach with nivolumab in advanced renal cell carcinoma in the TITAN-RCC trial. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.051.CrossRef

Jonasch E, et al. A first-in-human phase 1/2 trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.010.CrossRef

Titel: My personal highlights of ESMO 2019 regarding urogenital cancer
verfasst von: Dora Niedersüß-Beke
Publikationsdatum: 15.04.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00605-0

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Therapy management in bone sarcoma

The role of surgery in soft tissue sarcoma: Can we improve outcome and function towards sporting activities?

Immunotherapy in hepatocellular carcinoma

Perioperative treatment of soft-tissue sarcoma

PARP inhibitors in the treatment of ovarian cancer

Thermal ablation—an option in curative treatment of HCC